Catalent, novo nordisk

Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
Novo Holdings Acquires Catalent: A Deal to Boost Weight-Loss Drug Production
Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent factories to Novo Nordisk for $11 billion,
Catalent And Novo Holdings Complete All Regulatory Closing Conditions For Merger
Catalent Inc. (CTLT) and Novo Holdings A/S announced that the companies have fulfilled all regulatory closing conditions for their
Novo’s takeover of Catalent set to proceed after FTC declines to challenge deal
Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the Federal Trade Commission decided not to challenge the deal. It’s expected to close in the coming days.
Novo Nordisk says Catalent buyout to close soon as regulatory conditions met
Novo Nordisk's (NVO) acquisition of three Catalent (CTLT) production sites to close soon as its parent wins regulatory nod for the $16.5B deal. Read more here.
European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent
The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of Novo Nordisk, one of the
Novo says Catalent deal regulatory closing conditions fulfilled
Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent
Novo Nordisk Set to Close Catalent Deal Without FTC Challenge
Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal.
Novo Nordisk to Invest $1.2 Billion in New Production Facility in Denmark
The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the ...
Novo Holdings’ acquisition of Catalent gains EC approval
Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...
FiercePharma9d
With green light from European Commission, Novo Holdings' proposed $16.5B Catalent buyout nears close
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...
BioSpace6d
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...
Indiana Daily Student9d
EU approves Novo’s Catalent acquisition, step forward for Bloomington plant workers
The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...
Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...